Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent

Journal of Medicinal Chemistry

Volumn 57, Issue 24, 2014, Pages 10304-10313

  Shao, Yong Xian ^a,b   Huang, Manna ^a,b   Cui, Wenjun ^b   Feng, Ling Jun ^a   Wu, Yinuo ^a   Cai, Yinghong ^a   Li, Zhe ^a   Zhu, Xinhai ^a   Liu, Peiqing ^a   Wan, Yiqian ^a   Ke, Hengming ^a,b   Luo, Hai Bin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(1 CYCLOPENTYL 4 HYDROXY 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL)AMINO] N (4 METHOXYPHENYL)ACETAMIDE; 2 [(1 CYCLOPENTYL 4 HYDROXY 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL)AMINO] N (4 METHOXYPHENYL)PROPANAMIDE; 2 [(1 CYCLOPENTYL 4 OXO 4,5 DIHYDRO 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL)AMINO] N (4 FLUOROPHENYL)PROPANAMIDE; 2 [(1 CYCLOPENTYL 4 OXO 4,5 DIHYDRO 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL)AMINO] N (4 METHOXYPHENYL) 4 METHYLPENTANAMIDE; 2 [(4 HYDROXY 1 ISOBUTYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL)AMINO] N (4 METHOXYPHENYL)PROPANAMIDE; 2 [(4 HYDROXY 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL)AMINO] N (4 METHOXYPHENYL)ACETAMIDE; 2 [(4 HYDROXY 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL)AMINO] N (4 METHOXYPHENYL)PROPANAMIDE; 2 [[1 (2 CHLOROPHENYL) 4 HYDROXY 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]AMINO] N (4 METHOXYPHENYL)PROPANAMIDE; 2 [[1 (2 CYCLOPENTYL) 4 HYDROXY 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]AMINO] N (4 METHOXYPHENYL)PROPANAMIDE; 6 CHLORO 1 CYCLOPENTYLL 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 OL; 6 CHLORO 1 ISOBUTYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 OL; 6 CHLORO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 OL; ANTIDIABETIC AGENT; BAY 73 6691; GLUCOSE 6 PHOSPHATASE; MESSENGER RNA; PF 04447943; PF 4181366; PF 4181633; PHOSPHODIESTERASE 9A INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); UNCLASSIFIED DRUG; 2-((1-CYCLOPENTYL-4-HYDROXY-1H-PYRAZOLO(3,4-D)PYRIMIDIN-6-YL)AMINO)-N-(4-METHOXYPHENYL)PROPANAMIDE; CYCLIC AMP PHOSPHODIESTERASE; PDE9A PROTEIN, HUMAN; PHOSPHOENOLPYRUVATE CARBOXYLASE KINASE; PROTEIN SERINE THREONINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONFORMATION; DRUG HALF LIFE; DRUG SELECTIVITY; HEPG2 CELL LINE; HYDROGEN BOND; IC50; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY FLUID; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYME ACTIVE SITE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER MICROSOME; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; WESTERN BLOTTING; X RAY CRYSTALLOGRAPHY;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; BLOTTING, WESTERN; BODY FLUIDS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE-6-PHOSPHATASE; HEP G2 CELLS; HUMANS; HYDROGEN BONDING; HYPOGLYCEMIC AGENTS; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHODIESTERASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRIMIDINONES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 84920146513     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500836h     Document Type: Article

References (50)

1. National Diabetes Data Group Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance Diabetes 1979, 28, 1039-1057
2. Anfossi, G.; Mularoni, E. M.; Burzacca, S.; Ponziani, M. C.; Massucco, P.; Mattiello, L.; Cavalot, F.; Trovati, M. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM Diabetes Care 1998, 21, 121-126
3. Rizzo, N. O.; Maloney, E.; Pham, M.; Luttrell, I.; Wessells, H.; Tateya, S.; Daum, G.; Handa, P.; Schwartz, M. W.; Kim, F. Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding Arterioscler., Thromb., Vasc. Biol. 2010, 30, 758-765
4. Tateya, S.; Rizzo, N. O.; Handa, P.; Cheng, A. M.; Morgan-Stevenson, V.; Daum, G.; Clowes, A. W.; Morton, G. J.; Schwartz, M. W.; Kim, F. Endothelial NO/cGMP/VASP signaling attenuates Kupffer cell activation and hepatic insulin resistance induced by high-fat feeding Diabetes 2011, 60, 2792-2801
5. Goud, A. P.; Goud, P. T.; Diamond, M. P.; Gonik, B.; Abu-Soud, H. M. Activation of the cGMP signaling pathway is essential in delaying oocyte aging in diabetes mellitus Biochemistry 2006, 45, 11366-11378
6. Maurice, D. H.; Ke, H.; Ahmad, F.; Wang, Y.; Chung, J.; Manganiello, V. C. Advances in targeting cyclic nucleotide phosphodiesterases Nat. Rev. Drug Discovery 2014, 13, 290-314
7. Conti, M.; Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling Annu. Rev. Biochem. 2007, 76, 481-511
8. Omori, K.; Kotera, J. Overview of PDEs and their regulation Circ. Res. 2007, 100, 309-327
9. Ke, H.; Wang, H.; Ye, M. Structural insight into the substrate specificity of phosphodiesterases Handb. Exp. Pharmacol. 2011, 204, 121-134
10. Degerman, E.; Belfrage, P.; Manganiello, V. C. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3) J. Biol. Chem. 1997, 272, 6823-6826
11. Guirguis, E.; Hockman, S.; Chung, Y. W.; Ahmad, F.; Gavrilova, O.; Raghavachari, N.; Yang, Y.; Niu, G.; Chen, X.; Yu, Z. X.; Liu, S.; Degerman, E.; Manganiello, V. A role for phosphodiesterase 3B in acquisition of brown fat characteristics by white adipose tissue in male mice Endocrinology. 2013, 154, 3152-3167
12. Ghorbani, A.; Omrani, G. R.; Hadjzadeh, M. A.; Varedi, M. Proinsulin C-peptide inhibits lipolysis in diabetic rat adipose tissue through phosphodiestrase-3B enzyme Horm. Metab Res. 2013, 45, 221-225
13. Genders, A. J.; Bradley, E. A.; Rattigan, S.; Richards, S. M. cGMP phosphodiesterase inhibition improves the vascular and metabolic actions of insulin in skeletal muscle Am. J. Physiol. Endocrinol. Metab. 2011, 301, E342-E350
14. Thompson, C. S. Diabetic nephropathy: Treatment with phosphodiesterase type 5 inhibitors World J. Diabetes 2013, 4, 124-129
15. Nawrocki, A. R.; Rodriguez, C. G.; Toolan, D. M.; Price, O.; Henry, M.; Forrest, G.; Szeto, D.; Keohane, C. A.; Pan, Y.; Smith, K. M.; Raheem, I. T.; Cox, C. D.; Hwa, J.; Renger, J. J.; Smith, S. M. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance Diabetes 2014, 63, 300-311
16. Fryburg, D. A.; Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors. WO 03/037432 A1, 2003.
17. Deninno, M. P.; PDE9 inhibitors for treating cardiovascular disorders. WO 03/037899, 2003; Pfizer Inc.
18. Bell, A. S.; PDE9 inhibitors for treating type 2 diabetes, metabolic syndrome, and cardiovasculate disease. WO 2004/096811, 2004.
19. Black, S. C.; Gibbs, E. M.; McNeish, J. D. Phosphodiesterase 9 inhibition as treatment for obesity-related conditions. WO 2005/041972, 2005.
20. Deninno, M. P.; Andrews, M.; Bell, A. S.; Chen, Y.; Eller-Zarbo, C.; Eshelby, N.; Etienne, J. B.; Moore, D. E.; Palmer, M. J.; Visser, M. S.; Yu, L. J.; Zavadoski, W. J.; Michael Gibbs, E. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents Bioorg. Med. Chem. Lett. 2009, 19, 2537-2541
21. Wunder, F.; Tersteegen, A.; Rebmann, A.; Erb, C.; Fahrig, T.; Hendrix, M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line Mol. Pharmacol. 2005, 68, 1775-1781
22. Verhoest, P. R.; Fonseca, K. R.; Hou, X.; Proulx-Lafrance, C.; Corman, M.; Helal, C. J.; Claffey, M. M.; Tuttle, J. B.; Coffman, K. J.; Liu, S.; Nelson, F.; Kleiman, R. J.; Menniti, F. S.; Schmidt, C. J.; Vanase-Frawley, M.; Liras, S. Design and discovery of 6-[(3 S,4 S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2 H -pyran-4-yl)-1,5-dihydro-4 H -pyrazolo[3,4- d ]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders J. Med. Chem. 2012, 55, 9045-9054
23. Verhoest, P. R.; Proulx-Lafrance, C.; Corman, M.; Chenard, L.; Helal, C. J.; Hou, X.; Kleiman, R.; Liu, S.; Marr, E.; Menniti, F. S.; Schmidt, C. J.; Vanase-Frawley, M.; Schmidt, A. W.; Williams, R. D.; Nelson, F. R.; Fonseca, K. R.; Liras, S. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy J. Med. Chem. 2009, 52, 7946-7949
24. Meng, F.; Hou, J.; Shao, Y. X.; Wu, P. Y.; Huang, M.; Zhu, X.; Cai, Y.; Li, Z.; Xu, J.; Liu, P.; Luo, H.-B.; Wan, Y.; Ke, H. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design J. Med. Chem. 2012, 55, 8549-8558
25. van der Staay, F. J.; Rutten, K.; Bärfacker, L.; Devry, J.; Erb, C.; Heckroth, H.; Karthaus, D.; Tersteegen, A.; van Kampen, M.; Blokland, A.; Prickaerts, J.; Reymann, K. G.; Schröder, U. H.; Hendrix, M. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents Neuropharmacology 2008, 55, 908-918
26. Hutson, P. H.; Finger, E. N.; Magliaro, B. C.; Smith, S. M.; Converso, A.; Sanderson, P. E.; Mullins, D.; Hyde, L. A.; Eschle, B. K.; Turnbull, Z.; Sloan, H.; Guzzi, M.; Zhang, X.; Wang, A.; Rindgen, D.; Mazzola, R.; Vivian, J. A.; Eddins, D.; Uslaner, J. M.; Bednar, R.; Gambone, C.; Le-Mair, W.; Marino, M. J.; Sachs, N.; Xu, G.; Parmentier-Batteur, S. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943(6-[(3 S,4 S)-4-methyl-1-(pyrimidin-2- ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2 H -pyran-4-yl)-1,5-dihydro-4 H -pyrazolo[3,4- d ]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents Neuropharmacology 2011, 61, 665-676
27. Vardigan, J. D.; Converso, A.; Hutson, P. H.; Uslaner, J. M. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task J. Neurogenet. 2011, 25, 120-126
28. Liddie, S.; Anderson, K.; Paz, A.; Itzhak, Y. The effect of phosphodiesterase inhibitors on extinction of cocaine-induced conditioned place preference in mice J. Psychopharmacol. 2012, 26, 1375-1382
29. Kroker, K. S.; Rast, G.; Giovannini, R.; Marti, A.; Dorner-Ciossek, C.; Rosenbrock, H. Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP Neuropharmacology 2012, 62, 1964-1974
30. Kleiman, R. J.; Chapin, D. S.; Christoffersen, C.; Freeman, J.; Fonseca, K. R.; Geoghegan, K. F.; Grimwood, S.; Guanowsky, V.; Hajós, M.; Harms, J. F.; Helal, C. J.; Hoffmann, W. E.; Kocan, G. P.; Majchrzak, M. J.; McGinnis, D.; McLean, S.; Menniti, F. S.; Nelson, F.; Roof, R.; Schmidt, A. W.; Seymour, P. A.; Stephenson, D. T.; Tingley, F. D.; Vanase-Frawley, M.; Verhoest, P. R.; Schmidt, C. J. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo J. Pharmacol. Exp. Ther. 2012, 341, 396-409
31. Claffey, M. M.; Helal, C. J.; Verhoest, P. R.; Kang, Z.; Fors, K. S.; Jung, S.; Zhong, J.; Bundesmann, M. W.; Hou, X.; Lui, S.; Kleiman, R. J.; Vanase-Frawley, M.; Schmidt, A. W.; Menniti, F.; Schmidt, C. J.; Hoffman, W. E.; Hajos, M.; McDowell, L.; O'Connor, R. E.; Macdougall-Murphy, M.; Fonseca, K. R.; Becker, S. L.; Nelson, F. R.; Liras, S. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors J. Med. Chem. 2012, 55, 9055-9068
32. Wang, H.; Luo, X.; Ye, M.; Hou, J.; Robinson, H.; Ke, H. Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis J. Med. Chem. 2010, 53, 1726-1731
33. Ke, H.; Wang, H. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity Curr. Top. Med. Chem. 2007, 7, 391-403
34. Stephen, H. C.; Robin, W. Drug Disposition and Pharmacokinetics: From Principles to Applications; John Wiley & Sons, Ltd.: Hoboken, NJ, 2011.
35. Accelrys Discovery Studio, version 2.5.5; Accelrys Software Inc.: San Diego, CA, 2010.
36. Wu, G.; Robertson, D. H.; Brooks, C. L.; Vieth, M. Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm J. Comput. Chem. 2003, 24, 1549-1562
37. Venkatachalam, C. M.; Jiang, X.; Oldfield, T.; Waldman, M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites J. Mol. Graphics Modell. 2003, 21, 289-307
38. Gilbert, A. M.; Nowak, P.; Brooijmans, N.; Bursavich, M. G.; Dehnhardt, C.; Santos, E. D.; Feldberg, L. R.; Hollander, I.; Kim, S.; Lombardi, S.; Park, K.; Venkatesan, A. M.; Mallon, R. Novel purine and pyrazolo[3,4- d ]pyrimidine inhibitors of PI3 kinase-alpha: hit to lead studies Bioorg. Med. Chem. Lett. 2010, 20, 636-639
39. Huai, Q.; Wang, H.; Zhang, W.; Colman, R. W.; Robinson, H.; Ke, H. Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 9624-9629
40. Hou, J.; Xu, J.; Liu, M.; Zhao, R.; Luo, H.-B.; Ke, H. Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine PLoS One 2011, 6, e18092
41. Wang, H.; Liu, Y.; Huai, Q.; Cai, J.; Zoraghi, R.; Francis, S. H.; Corbin, J. D.; Robinson, H.; Xin, Z.; Lin, G.; Ke, H. Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development J. Biol. Chem. 2006, 281, 21469-21479
42. Wang, H.; Liu, Y.; Chen, Y.; Robinson, H.; Ke, H. Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7 J. Biol. Chem. 2005, 280, 30949-30955
43. Wang, H.; Yan, Z.; Yang, S.; Cai, J.; Robinson, H.; Ke, H. Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity Biochemistry 2008, 47, 12760-12768
44. Wang, H.; Liu, Y.; Hou, J.; Zheng, M.; Robinson, H.; Ke, H. Structural insight into substrate specificity of phosphodiesterase 10 Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 5782-5787
45. Huai, Q.; Wang, H.; Sun, Y.; Kim, H. Y.; Liu, Y.; Ke, H. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity Structure 2003, 11, 865-873
46. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 1997, 276, 307-326
47. Jones, T. A.; Zou, J.-Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models Acta Crystallogr. 1991, A47, 110-119
48. Brünger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography and NMR system: a new software suite for macromolecular structure determination Acta Crystallogr. 1998, D54, 905-921
49. Kim, Y. D.; Park, K. G.; Lee, Y. S.; Park, Y. Y.; Kim, D. K.; Nedumaran, B.; Jang, W. G.; Cho, W. J.; Ha, J.; Lee, I. K.; Lee, C. H.; Choi, H. S. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP Diabetes 2008, 57, 306-314
50. Luo, Z.; Sheng, J.; Sun, Y.; Lu, C.; Yan, J.; Liu, A.; Luo, H.-B.; Huang, L.; Li, X. Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen J. Med. Chem. 2013, 56, 9089-9099